Likewise, other studies have demonstrated a combination of PD-1/PD-L1 inhibitors with anti-angiogenesis drugs to inhibit angiogenesis and induce cancer immunity in lung, kidney, and liver carcinomas [86–90]. This evidence concerns the gene CD274 and hepatocellular carcinoma.